Affordable Access

deepdyve-link
Publisher Website

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients

Authors
  • Calich, Ana Luisa
  • Puéchal, Xavier
  • Pugnet, Grégory
  • London, Jonathan
  • Terrier, Benjamin
  • Charles, Pierre
  • Mouthon, Luc
  • Guillevin, Loïc1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 2, 11
  • 1 National Referral Center for Rare Systemic Autoimmune Diseases
  • 2 Service de Médecine Interne
  • 3 Hôpital Cochin
  • 4 Assistance Publique-Hôpitaux de Paris
  • 5 Université Paris Descartes
  • 6 Division of Rheumatology
  • 7 University of São Paulo School of Medicine
  • 8 Institut Cochin
  • 9 INSERM U1016
  • 10 CNRS UMR 8104
  • 11 CHU Purpan
Type
Published Article
Journal
Journal of Autoimmunity
Publisher
Elsevier BV
Publication Date
Jan 01, 2014
Accepted Date
Mar 09, 2014
Identifiers
DOI: 10.1016/j.jaut.2014.03.002
Source
Elsevier
Keywords
License
Unknown

Abstract

•This is a long follow-up study of a single-center cohort of patients with granulomatosis with polyangiitis (Wegener's).•Rituximab was effective for remission induction and maintenance therapy, despite low doses of steroids and rituximab.•Low-dose rituximab in a routine time-based protocol for maintenance therapy appears to be effective with low toxicity.

Report this publication

Statistics

Seen <100 times